Introduction {#s1}
============

Knowing which molecules are specifically altered in neuropsychiatric patients would represent a crucial step towards uncovering mechanisms of the development of neuropshychiatric diseases and generating more successful therapeutic strategies. An immediate impact of identifying such molecules would be access to a set of biomarkers to help define and monitor populations at risk.

MicroRNAs (miRNAs, miRs) may up- or down-regulate the translation of messenger RNA (mRNA) or render it unstable, and have recently been proposed as biomarkers for brain neoplasms, degenerative diseases, autism, and schizophrenia [@pone.0048814-DeSmaele1]. Dysregulation of miRNAs in brains of patients diagnosed with schizophrenia (SZ) [@pone.0048814-Beveridge1] and other neuropsychiatric disorders is plausible considering that many miRNAs are expressed in human brain [@pone.0048814-Sempere1] where they regulate neuronal development [@pone.0048814-Ambros1] and differentiation [@pone.0048814-Kim1] including dendritic spine development [@pone.0048814-Schratt1] and plasticity [@pone.0048814-Presutti1],[@pone.0048814-Fiore1], as well as cognitive functions [@pone.0048814-Ashraf1]. A group of miRNAs has been recently designated as "misexpressed" in the prefrontal cortices (PFCs) of both SZ and bipolar disorder (BD) patients [@pone.0048814-Moreau1]. The target analysis of another reported set of differentially expressed miRNAs in the PFCs of SZ patients revealed many genes implicated in signaling pathways [@pone.0048814-Perkins1]. While a specific BD miRNA profile has not yet been established, alterations in neurochemical regulation including an excess in signaling activity have been associated with BD [@pone.0048814-Vawter1].

Signaling activity in neurons commonly requires the release of signaling molecules from their specific secretory vesicles [@pone.0048814-Suudhof1]. Exosomes are secretory vesicles defined by size (30--90 nm), buoyant density (∼1.1--1.2 g/ml), lipid composition, and the presence as well as the absence of specific marker proteins [@pone.0048814-Smalheiser1]. Exosomes represent the alternative route for the content of multivesicular bodies (MVBs, exosomal precursor organelles) destined for degradation in lyzosomes. Rather then being degraded, MVBs' intraluminal vesicles are fused with the plasma membrane and secreted into the extracellular space as exosomes [@pone.0048814-vanNiel1]. Because of the specific molecules on their surface, including cell-adhesion proteins, exosomes can be incorporated by specific recipient cells [@pone.0048814-vanNiel1],[@pone.0048814-Fevrier1]. The exosomal involvement in neuronal signaling was suggested by the presence of MVBs in dendritic spines [@pone.0048814-Blanpied1],[@pone.0048814-Cooney1] and by the resemblance of synaptic spinules (evaginations of the postsynaptic membrane that bud into presynaptic axon) to exosomes [@pone.0048814-Tarrant1],[@pone.0048814-Spacek1]. The role of exosomes in synaptic activity is further corroborated by the dependence of long term potentiation (LTP)-induced structural spine plasticity on exocytic trafficking from recycling endosomes [@pone.0048814-Park1].

Cultured primary cortical neurons and astrocytes do release exosomes [@pone.0048814-Faure1]. Studies of exosomal cargo in neurons and microglia have revealed proteins important for the development of neurodegenerative diseases such as Alzheimer's disease [@pone.0048814-Okabayashi1]--[@pone.0048814-Yuyama1] and Parkinson's disease [@pone.0048814-Emmanouilidou1]. Exosomes in neuronal cell lines have also been shown to transfer prions [@pone.0048814-Vella1] as well as wild-type and mutant superoxide dismutase, thus propagating cell-to-cell mutant toxicity [@pone.0048814-Gomes1]. Microarray analysis of exosomal content from mouse bone marrow mast cells and human and mouse mast cell lines has established the presence of mRNA and miRNA [@pone.0048814-Valadi1]. A new name for this mRNA - "exosomal shuttle RNA" [@pone.0048814-Valadi1] - has been proposed to underscore the ability of exosomes to mediate the exchange of genetic material between cells. Changes in exosomal miRNAs have been reported in patients diagnosed with Alzheimer's disease [@pone.0048814-Cogswell1], while RNA content from the glioblastoma microvesicles was shown to provide diagnostic biomarkers [@pone.0048814-Skog1]. Postmortem human PFC samples have been used to successfully generate miRNA profiles [@pone.0048814-Perkins1]. Here we report the results of exosomal miRNA expression analysis in PFCs from patients diagnosed with SZ, BD, and mental illness-free controls. We have observed aberrations in SZ and BD samples in comparison to controls, suggesting both common and differential pathobiology. These results may forecast reproducible, disease-associated changes of miRNA expression serving as biomarkers in exosomes, cellular particles potentially obtainable from the cerebrospinal fluid (CSF) of living patients.

Materials and Methods {#s2}
=====================

Human Brain Tissue {#s2a}
------------------

Written informed consent was obtained from the next of kin for the use of the postmortem brain tissue by the following sources of frozen PFC (Brodmann area 9, BA9): BrainNet Europe II, a consortium of 18 brain banks across Europe (BNE; cases SZ 1--6, BD 5--9, and C 6--10), McLean 66 Cohort Collection at Harvard Brain Tissue Resource Center (McLean; cases SZ 7 and 8, BD 1--4, and C 1--5), and autopsy service at Boston Medical Center (BMC; cases C 11--13) ([Table 1](#pone-0048814-t001){ref-type="table"}).
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###### Analyzed human prefrontal cortices (BA9).
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  Case andDisease    Age   Gender/Hemisphere   PMI                         Neuropathology and pertinentclinical history                        Source   RIN   Experiment
  ----------------- ----- ------------------- ------ ---------------------------------------------------------------------------------------- -------- ----- ------------
  SZ1                74         M/left          6                    BB II, alpha-synuclein immunoreactivityin few SN neurons                   BNE     8.3      L, P
  SZ2                65         M/left         3.5                             BB I, lacunar infarct in the caudate                             BNE     8.3      L, P
  SZ3                82         M/left         4.5                     BB VI, amyloid angiopathy, lacunarinfarct in putamen                     BNE     9.1      L, P
  SZ4                77         M/left          6                             BB II, old infarct in the frontal lobe                            BNE     8.3      L, P
  SZ5                84         M/left         2.5                     BB II, amyloid angiopathy, argirofilicgrain disease                      BNE     8.3      L, P
  SZ6                79         M/left         2.5    multiple infarcts in the teritories of middleand posterior cerebral artery circulation    BNE     7.8      L, P
  SZ7                63         M/right        22.3                                            BB I                                            McLean   7.6       L
  SZ8                35         M/left          28                BB I, non-specific fronto-temporo-parietaland thalamic atrophy               McLean   6.1       L
  BD1                40         M/left         30.8                       acute hypoxic changes, focalarteriolosclerosis                       McLean   6.7       L
  BD2                38         M/left          22        parietal cortex infarct, focal acute hypoxicchanges, focal arteriolosclerosis        McLean   7.9       L
  BD3                50         M/right        30.5                                 no neuropathology reported                                 McLean   7.1       L
  BD4                74         M/right         25                                  no neuropathology reported                                 McLean   6.6       L
  BD5                73         M/right        5.3                 BB II, temporal SPs, small old corticaland striatal infarcts                 BNE     6.2      L, P
  BD6                70         M/left         6.4               BB III, many SP, few NP, contusions (dueto fall); alcohol abuse                BNE     6.2      L, P
  BD7                68         M/left          NA                                             BB I                                             BNE     5.5       P
  BD8                93         M/left          6                                              BB I                                             BNE     5.1       P
  BD9                90         F/left         6.5                                       BB I-II, rare SP                                       BNE     7.7       P
  C1                 67         M/right        22.3                 BB I, lacunar infarcts in putamen, focalarteriolosclerosis                 McLean   8.0       L
  C2                 37         M/right        18.7                    minimal acute hypoxic-ischemic changein hippocampus                     McLean   6.4       L
  C3                 38         M/left         28.8                                 no neuropathology reported                                 McLean   7.7       L
  C4                 50         M/left         24.1                                            BB I                                            McLean   6.2       L
  C5                 40         M/right         28                                  no neuropathology reported                                 McLean   7.1       L
  C6                 68         M/left         10.2                                 no neuropathology reported                                  BNE     6.4      L, P
  C7                 71         M/left         7.6                          BB I, lacunar infarct in internal capsule                           BNE     6.1       P
  C8                 82         F/left          7            severe atherosclerosis in the circle ofWillis, focal gliosis in striatum           BNE     6.1       P
  C9                 96         M/right        5.4         BB I, rare SP, rare NP, hypoxic-ischemicchanges in striatum and hippocampus          BNE     6.0       P
  C10                65         F/left         12.8                                     no neuropathology                                       BNE     8.1       P
  C11                80         M/left          17                                      no neuropathology                                       BMC     5.9       P
  C12                72         F/left          23                                      no neuropathology                                       BMC     5.1       P
  C13                68         F/left          25                                      no neuropathology                                       BMC     7.0       P

SZ =  schizophrenia; BD =  bipolar disorder; C =  controls.

BB =  Braak and Braak.

L =  Luminex; P =  qPCR.

Extractions of Exosome-containing Pellets {#s2b}
-----------------------------------------

Exosome extraction protocol from primary and cultured cells [@pone.0048814-Valadi1] was modified to obtain exosome-containing pellets from frozen brain tissue that was previously evaluated for RNA integrity ([Figure S1](#pone.0048814.s001){ref-type="supplementary-material"}). Only the brain tissue samples yielding an RNA integrity number (RIN) of ≥5.1 (range 5.1--9.1, [Table 1](#pone-0048814-t001){ref-type="table"}) and thus well within accepted standards [@pone.0048814-Durrenberger1] were used to obtain exosome-containing pellets. From the original frozen prefrontal cortex stored at −80°C procured by each brain bank, we cut approximately 600 mg of grey matter using a razor blade. The frozen tissue was put in 1 ml phosphate-buffered saline, pH 7.4 (PBS, 4°C), gently teased with a small spatula, and vortexed (VWR mini-vortexer) on a medium power. Each tube was centrifuged at 300×g for 10 min, decanted, centrifuged twice at 1,200×g for 10 min with decanting in between, and finally filtered through a 0.2 um syringe filter (Millipore, Carrigtowhill, Cork, Ireland). The filtrate was centrifuged twice at 10,000×g for 30 min with decanting in between. The final centrifugation to obtain exosome-containing pellets was performed at 22,000×g for 22 hrs. All centrifugations were performed at 2°C.

As a control exosomal extraction procedure, exosomes from cultured human H4 cells (HTB 148 ATCC, Manassas, VA, USA) were prepared as previously published [@pone.0048814-Fevrier1]--[@pone.0048814-Thery1] with minor modifications. Briefly, H4 cells were cultured in OPTIMEM medium (Life Technologies) without serum or antibiotics. After 48 hours, conditioned medium was collected and centrifuged for 5 min at 500×g at 4°C to remove cell debris. The supernatants were then sequentially centrifuged at 300×g (10 min) and twice at 2,000×g (10 min), 4°C. The supernatant was filtered through a 0.45 um (Whatman, Florham Park, NJ) and 0.22 um (Millipore, Carrigtowhill, Cork, Ireland) filter, and centrifuged for 1 hr at 10,000×g at 4°C. The supernatant was removed and then subjected to ultracentrifugation at 100,000×g for 2 hours at 4°C. The supernatant was collected and the exosome-containing pellet was re-suspended in PBS for Western Blotting.

Transmission Electron Microscopy (TEM) and Immuno-gold Labeling {#s2c}
---------------------------------------------------------------

For morphological identification of exosomes, the pellets were either embedded in a hydrophilic resin upon fixation in TEM fixative (4% paraformaldehyde, 0.2% glutaraldehyde, in 0.2 M cacodylate buffer, pH 7.2.) or directly adsorbed to a carbon-coated grid that has been made hydrophilic by an exposure to a glow discharge (30 sec). Upon blocking with 1% Bovine Serum Albumin (BSA), grids with pellets were incubated in primary antibody (CD63, *BD Pharmingen*, and GAPDH, *Ambion*) solutions in 1% BSA, rinsed in PBS, exposed to either bridging antibody first or directly to protein A-gold (5 nM) solution in 1% BSA, rinsed in PBS, and finally in water. Excess liquid was removed with a filter-paper (Whatman \#1). Optional negative staining was achieved by incubation in 0.75% uranyl formate for 30 seconds. The examination was carried out in a JEOL 1200EX TEM or a TecnaiG^2^ Spirit BioTWIN and images were recorded with an *AMT 2k CCD* camera.

Western Blotting {#s2d}
----------------

The expression of an exosomal marker flotillin-2 [@pone.0048814-Strauss1] in the exosomal preparations from frozen postmortem PFC was compared to the flotillin-2 expression in the cell-culture-derived exosomal preparations described above. Equal protein amounts (2.5 mg/ml) from each exosome-containing pellet reconstituted in PBS and respective supernatant were blotted with anti-flotillin-2 antibody (*BD Transduction Laboratories*, 1∶1,000).

Isolation, Purification, and Linear Amplification of miRNA from Exosome-containing Pellets {#s2e}
------------------------------------------------------------------------------------------

Exosome-containing pellets re-suspended in 20 ul of PBS were incubated with 0.4 mg/ml of RNase A/T1 (*Fementas*) for 10 min at 37°C. RNase was inactivated by adding 20 units/ul of *SuperRase-in* RNase inhibitor (*Ambion*) for 10 min at 25°C. The RNase treatment destroyed the higher molecular weight extra-exosomal cellular RNAs and preserved the small RNAs contained in the exosomes, i.e. ribosomal RNA and miRNA ([Figure S2](#pone.0048814.s002){ref-type="supplementary-material"}). Upon RNase inactivation, 60 ul of miRNA extraction buffer (*Arcturus*) was added, followed by an incubation at 42°C for 30 min and purification using *PicoPure* RNA Isolation Kit (*Lifetech*). The expected size range of miRNAs (∼19--28 nucleotides, nt) and pre-miRNAs (45--60 nt) were well-represented in the purified preparations ([Figure S2](#pone.0048814.s002){ref-type="supplementary-material"}). Because *Luminex* profiling system operates with inputs of 2.5--5 ug of total RNA per sample, we needed to ensure that our samples are sufficiently enriched for miRNA. To that end, we used *Invitrogen NCode* miRNA amplification system according to the manufacturer's protocol to linearly amplify miRNA in our material ([Table S2](#pone.0048814.s005){ref-type="supplementary-material"}). We found that this amplification step upon above described RNA treatment did not induce changes in the RNA profile ([Figure S3](#pone.0048814.s003){ref-type="supplementary-material"}).

Luminex miRNA Assay {#s2f}
-------------------

We performed miRNA expression analysis using a FlexMAP3D instrument by (Luminex Corporation, Austin, TX) and a manufacturer's assay for 312 miRNA ([Table S1](#pone.0048814.s004){ref-type="supplementary-material"}). This assay uses 5.6 um polystyrene micro-beads each of which contains a mixture of two fluorescent dyes that enable the beads to be identified as one of a specific set. Oligonucleotides, specific for each of our 312 miRNA assayed, were attached to the beads according to the manufacturer's protocol. The beads, upon incubation with miRNA containing samples, were passed through a fluidic tube that causes the micro-spheres to line up in single file before they pass through the detection chamber that contains two lasers. One of the laser beams classifies each bead into the appropriate bead set, while the other scans the beads for the presence of fluorescent reporter molecules and quantifies the number of reporter molecules on each bead. All 312 miRNA were assayed simultaneously in each sample. Intra-normalization of the obtained expression values was performed according to the *Luminex* protocol. Negative values were considered "0" because they indicate the expression below the background, i.e. the absence of a specific miRNA signal ([Table S1](#pone.0048814.s004){ref-type="supplementary-material"}).

Statistical Analysis of Luminex miRNA Expression Data {#s2g}
-----------------------------------------------------

Student's t-tests and statistical software packages including an *Excel* plug-in named Significance Analysis of Microarrays (SAM) [@pone.0048814-Tusher1],[@pone.0048814-Efron1] and an *R* package named Prediction Analysis of Microarrays (PAM) [@pone.0048814-Tibshirani1] were used to analyze *Luminex* expression data on 312 miRNAs from the prefrontal cortex of 8 SZ, 6 BD, and 6 control samples ([Table 1](#pone-0048814-t001){ref-type="table"} and [Table S1](#pone.0048814.s004){ref-type="supplementary-material"}). Because the statistical analysis of these data involves multiple comparisons we applied Bonferroni Step-down Holm Correction [@pone.0048814-Holm1] to Student's t-test outcomes \[0.05/(312--number of miRNAs ranked higher)\], resulting in a stricter threshold for significance ([Table S1](#pone.0048814.s004){ref-type="supplementary-material"}). Next, we used SAM and PAM because they provide multiclass testing [@pone.0048814-Tusher1]--[@pone.0048814-Tibshirani1] while a simple t-test only enables analysis between two groups. Multiclass testing was a necessary tool to identify a set of miRNAs that could be used to differentiate between all three groups. Both SAM and PAM use a modified z-score statistic [@pone.0048814-Tusher1]--[@pone.0048814-Tibshirani1] to produce a ranked list of candidate biomarker miRNAs. The adjustment for codependency of expression was performed as local False Discovery Rate (FDR) [@pone.0048814-Efron1], [@pone.0048814-Storey1] presented in [Tables 2](#pone-0048814-t002){ref-type="table"} and [3](#pone-0048814-t003){ref-type="table"}. FDR is a method of permutation testing [@pone.0048814-Benjamini1] that evaluates the risk of Type 1 error. Local FDR is an FDR assessment of not only a single miRNA, but also its "neighbors", i.e. other closely ranked miRNAs. In this way, a co-dependency is accounted for. Cluster analysis [@pone.0048814-Tibshirani1] was applied to those miRNAs that had "0″ q-values in SAM ([Tables 2](#pone-0048814-t002){ref-type="table"} and [3](#pone-0048814-t003){ref-type="table"}). Clustering was carried out through use of 2\*(1-cc) where cc equals a correlation between the cubed root of a single miRNA expression value for a sample and the average of cube-rooted values for all samples in the cluster it joins at that time point. The highest possible correlation between samples is 1 and the lowest is 0, resulting in a dendrogram that presents the clustered samples on a scale of 0 to 2. The dendrogram begins clustering miRNA with most similar expression patterns at the bottom of the graph and then additional miRNA are added to existing clusters as the graph is assembled vertically. In order to assess the predictive power of SAM-ranked miRNAs, the misclassification rate [@pone.0048814-Tibshirani1]--[@pone.0048814-Tibshirani2] was established as a means to classify clinical groups. A low misclassification rate indicates that a miRNA or a set of miRNAs is a reliable predictor of a group phenotype (a biomarker). Because of the limited number of cases available for analysis, we performed Wilcoxon test to supplement our findings ([Table S3](#pone.0048814.s006){ref-type="supplementary-material"}).

10.1371/journal.pone.0048814.t002

###### SAM test of *Luminex* miRNA expression data for all 3 examined groups of cases: SZ, BD, and C.
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  miRNA               z-score:C   z-score:BD   z-score: SZ   q-value(%)   local FDR(%)
  ------------------ ----------- ------------ ------------- ------------ --------------
  hsa-miR-31          −2.19709     −2.54002      3.55283         0        1.553882119
  hsa-miR-33          −2.17637     −1.95758      3.10046         0        2.433615922
  hsa-miR-96          −1.99363     −1.9829       2.9824          0        2.493468788
  hsa-miR-28          −1.40723     −1.68092      2.31611         0        2.300536436
  hsa-miR-30e-5p      −1.01353     −2.15639      2.37744         0        2.438595672
  hsa-miR-199a\*      −1.52064     −1.43723      2.21841         0        2.580013124
  hsa-miR-501         2.162398     −0.31372     −1.38651         0        2.585758655
  hsa-miR-504          1.9952      −0.30377     −1.26857         0        2.662187029
  hsa-miR-15b         −0.83294     −1.75496      1.94092         0        2.659473233
  hsa-miR-29c         2.068676     −0.39402     −1.25599         0        2.649467758
  hsa-miR-455         −1.49405     −1.08385      1.93342         0        2.611617439
  hsa-miR-380-3p      1.878938     −0.83204     −0.78517         0        2.621226767
  hsa-miR-323         −1.39982     −0.99834      1.79862         0        2.626487216
  hsa-miR-527         1.535186     0.010721     −1.15943         0        2.807651873
  hsa-miR-93          −1.31706     −0.81606      1.59984         0        2.851798957
  hsa-miR-32          −1.01365     −1.26054      1.70564         0         2.86415899
  hsa-miR-20b         −1.24865     −1.25458      1.87742         0        2.873400151
  hsa-miR-516-5p      1.441361     −0.31318     −0.84614         0        2.997241768
  hsa-miR-92          −1.12108     −0.96419      1.56396         0        3.013501643
  hsa-miR-30a-3p      −1.18983     −1.04924      1.67931         0        3.063908167
  hsa-miR-497          1.63309     −0.87672     −0.56728         0         3.16010056
  hsa-miR-498         1.256994     −0.11349     −0.85762     2.17948718   4.322678597
  hsa-miR-133b        −1.34128     −0.7324       1.55526     2.17948718   4.639798252
  hsa-miR-499         1.736963     −0.88259     −0.64078     2.17948718   4.738725328
  hsa-miR-10b         −0.72213     −1.17673      1.42415     2.17948718   4.878212949
  hsa-miR-202\*        −0.9101     −1.73414      1.98318     2.17948718   4.898293562
  hsa-miR-202         −0.14303     1.238359     −0.82149     2.17948718   5.065305767
  hsa-miR-149         1.490285     −0.74638     −0.55793     2.17948718   7.055913859
  hsa-miR-523          0.88386     0.910065     −1.34544     2.17948718    7.62760309
  hsa-miR-199b        −0.87254     −0.91723      1.34233     2.17948718   7.857837003
  hsa-miR-377         −0.97987     −1.24239      1.6667      3.73626374   9.314491623
  hsa-miR-518b        0.322664     0.980094     −0.97707     3.73626374   9.367786992
  hsa-miR-26b         1.336505     −0.36918     −0.72549     3.73626374   9.819393964
  hsa-miR-190         −1.44232     −1.32539      2.07578     3.73626374   10.24724163
  hsa-miR-326          −0.1038     1.199379     −0.82169     3.73626374   10.34765218
  hsa-miR-494         0.293894     0.910858     −0.90356     3.73626374   11.67285654
  hsa-miR-30e-3p      1.314221     −0.87488     −0.32951     3.73626374   12.18718064
  hsa-miR-512-3p      −0.17555     1.286875     −0.83349     3.73626374   12.89683212
  hsa-miR-302a\*      −0.47638     −1.30373      1.33509     3.73626374   13.04097715
  hsa-miR-19b         −0.28889     1.482134     −0.89494     3.73626374   13.11908036
  hsa-miR-302c        −0.12265     1.445789     −0.99236     4.84330484   14.25507383
  hsa-miR-218         0.521858     1.207283     −1.29686     4.84330484   14.36727552
  hsa-miR-338         −1.33167     −0.78432      1.58699     4.84330484   14.76902994
  hsa-miR-423         0.477963     0.812936     −0.96817     4.84330484   14.83356578
  hsa-miR-200c        −1.36615     −1.22514      1.94347     4.84330484   15.64595147
  hsa-miR-325         0.109128     1.083419     −0.89441     4.84330484   15.97503816
  hsa-miR-376b        1.029142     −0.00167      −0.7706     4.84330484   16.33334873
  hsa-miR-518c        −1.34489     −0.8751       1.66499     4.84330484   17.02063785
  hsa-miR-525\*       −0.93878     −1.06791      1.50502     4.84330484   17.14036115
  hsa-miR-125b        −0.86013     −0.85856      1.28902     4.84330484   17.17411684
  hsa-miR-299-3p      1.138288     −0.02057     −0.83829     4.84330484   18.19059244
  hsa-miR-363\*        0.02007     0.987996     −0.75605     4.84330484   18.33451874
  hsa-miR-542-3p      0.990978     0.007651     −0.74897     4.84330484   18.33773541
  hsa-miR-371         0.798332     0.593946     −1.04421     4.84330484   18.36737645
  hsa-miR-105         1.116132     0.542534      −1.244      7.00549451   22.95334699
  hsa-miR-449         0.914034     0.511142     −1.06888     7.00549451   23.04808523
  hsa-miR-370         1.088913     −0.34469     −0.55817     8.02968961   25.80170896
  hsa-miR-302d        −0.82471     −1.17696      1.50126     8.02968961   27.03187735
  hsa-miR-22          −1.01777     −1.05168      1.55209     8.02968961   27.64688383
  hsa-miR-17-5p       0.337338     0.922478     −0.94486     8.02968961   27.75618225
  hsa-miR-518a-2\*    1.201014     −0.2914      −0.68221     8.02968961   28.15873897
  hsa-miR-103         −0.48953     −0.73475      0.91821     8.02968961   28.42825986
  hsa-miR-520d\*      1.460088     −0.4613      −0.74909     9.90675991    29.0140902
  hsa-miR-18a\*       −0.89462     −0.66084      1.1666      9.90675991   30.34475207
  hsa-miR-210         −0.05258     1.249962     −0.89804     9.90675991   31.08028153
  hsa-miR-520e        −0.47633     −1.04849      1.14362     9.90675991   31.70287333
  hsa-miR-516-3p      1.187797     0.108884     −0.97251     9.90675991    32.5639352
  hsa-miR-329          −0.9053     1.414948     −0.38224     9.90675991   33.43751026
  hsa-miR-182         −1.07408     −0.71552      1.3422      9.90675991   33.54506373
  hsa-miR-380-5p       0.31583     0.983345     −0.97438     9.90675991    34.0190772
  hsa-miR-30c         −1.18267     0.402311      0.58527     9.90675991    35.0288034
  hsa-miR-106b        −0.08408     1.027975     −0.70792     11.587147    35.57300849
  hsa-miR-219         1.517496     −0.96688     −0.41296     11.587147    35.95711034
  hsa-miR-16          −0.92068     −0.50831      1.07174     11.587147    36.48103455
  hsa-miR-490         0.150144     0.835278     −0.73907     11.587147    37.01897704
  hsa-miR-367         0.797077     0.41705       −0.9106     11.587147    37.31177035
  hsa-miR-320         −0.25449     0.937805     −0.51249     11.587147     37.998358
  hsa-miR-135b        0.337006     0.857104     −0.89558     11.587147    38.84789583
  hsa-miR-206          −0.3697     0.94394      −0.43068     11.587147    39.10460163
  hsa-miR-526b\*      1.208306     −0.78313     −0.31888     11.587147    40.34787385
  hsa-miR-425         −0.85102     1.009775     −0.11907     11.587147    40.77866903
  hsa-miR-376a        0.920047     −0.1274      −0.59448     11.587147    40.92694087
  hsa-miR-503         0.888295     −0.13607     −0.56417     14.1171329   42.85245703
  hsa-miR-487a        0.162841     0.82095      −0.73784     14.1171329   43.30927731
  hsa-miR-106a        0.521766     0.595635     −0.83805     14.1171329   43.48858371
  hsa-miR-100         0.056388     −1.20747      0.86331     14.1171329   44.10398892
  hsa-let-7f          −0.93439     −0.05581      0.74264     14.1171329   44.67888809
  hsa-miR-511         0.310344     −1.0703       0.56996     14.1171329   44.90173075
  hsa-miR-544         1.131482     −0.56382     −0.42574     14.1171329   47.12197196
  hsa-miR-487b        −0.82112     −0.41659      0.92829     14.1171329   47.26591312
  hsa-miR-363         −1.27178     −0.56825      1.38003     14.1171329   47.48233294
  hsa-miR-376a\*      0.390564     0.732719     −0.84246     14.1171329   48.56245152
  hsa-miR-375         0.243853     0.644572     −0.66632     16.5048544   49.01224431
  hsa-miR-153          −0.9969     −1.14696      1.60789     16.5048544   49.40211523
  hsa-miR-431         −0.82106     −0.91197      1.29978     16.5048544   49.44548869
  hsa-miR-217         −0.99016     −0.31608      0.97968     16.5048544   49.52370084
  hsa-miR-362         −0.28573     −1.02521      0.98321     16.5048544   49.87006572
  hsa-miR-500         0.980354     −0.56183     −0.31389     16.5048544   50.74516842
  hsa-miR-372         −0.96458     −0.95534      1.43994     16.5048544   50.99446275
  hsa-miR-148a        0.828874     −1.04752      0.16398     16.5048544   51.40114981
  hsa-miR-10a         −0.64047     −0.52695      0.87556     16.5048544   52.40792839
  hsa-miR-433         −0.22833     0.946138     −0.53835     16.5048544   52.46791499
  hsa-miR-29b         0.620123     −1.14248      0.39177     16.5048544   52.72930619
  hsa-miR-382         −0.23578     0.894415     −0.49398     16.5048544   53.59705171
  hsa-miR-335          −0.3399     0.856229     −0.38725     16.5048544   53.75101383
  hsa-miR-381         −0.81724     −0.5501       1.02551     16.5048544   54.38769193
  hsa-miR-513         0.767999     0.015731      −0.5878     18.2605683   54.93952212
  hsa-miR-328         0.233808     0.700291     −0.70057     18.2605683   55.70006535
  hsa-miR-518e        −0.73833     −0.62201      1.02026     18.2605683   56.00690632
  hsa-miR-301         0.120635     0.905541     −0.76963     18.2605683   56.02980543
  hsa-miR-25          −0.66639     −0.6356       0.97649     18.2605683   56.32551846
  hsa-miR-518d        0.155299     0.838491     −0.74534     19.8489011   58.23570838
  hsa-miR-342         0.551634     −1.20248      0.48813     22.5464191   59.93768974
  hsa-miR-521         −0.96506     −0.45523      1.06522     22.5464191    60.4907877
  hsa-miR-520a         0.84235     −1.11148      0.20185     22.5464191   60.95727772
  hsa-miR-409-5p      0.882507     −0.76108     −0.09107     22.5464191   61.30748083
  hsa-miR-485-3p      0.386518     0.492904     −0.65957     24.0302433   62.62241634
  hsa-miR-200a        0.092787     −0.91805      0.61894     25.0641026   63.41566145
  hsa-miR-29a         0.482776     0.519518     −0.75172     25.0641026   63.78211013
  hsa-miR-429         0.055713     0.792367     −0.63606     25.0641026   63.82820222
  hsa-miR-125a        0.805608     −0.59199     −0.16021     28.4739454   65.48468447
  hsa-miR-502         0.754098     −0.67512     −0.05923     28.4739454   65.82932368
  hsa-miR-17-3p       −0.43522     −0.7476       0.88711     28.4739454   66.19614625
  hsa-miR-148b        0.174623     −0.94181      0.57539     28.4739454   66.43951644
  hsa-miR-368         0.743991     −0.88733      0.10751     28.4739454   67.12123684
  hsa-miR-142-3p      −0.20516      −1.124       0.99687     31.1598558   67.73036369
  hsa-miR-205         0.249306     0.845495      −0.8211     31.1598558   67.86858747
  hsa-miR-373\*       0.052207     0.60096      −0.48988     31.1598558    68.0705944
  hsa-miR-517\*       −0.63383     −0.14053      0.58077     32.4408284   68.51734889
  hsa-miR-186         −0.35485     0.80983      −0.34124     32.4408284   68.75244349
  hsa-miR-452\*       −0.27916     −0.91071      0.8924      32.4408284   70.00183058
  hsa-miR-181d        0.830156     −0.52455      −0.2292     32.4408284   70.12549652
  hsa-miR-489         −0.56225     −0.14396      0.52966     32.4408284   70.13050269
  hsa-miR-183         0.159174     0.686645     −0.63436     32.4408284   70.19307622
  hsa-miR-30d         −0.43691     0.770014     −0.24983     32.4408284   70.23265424
  hsa-miR-483         0.815477     −0.84234      0.02015     32.4408284   70.60907344
  hsa-let-7a          −0.70813     0.463107      0.18377     32.4408284   70.71775515
  hsa-miR-451         −1.23771     0.247949      0.74232     32.4408284   70.91507517
  hsa-miR-221         −0.87556     −0.58425      1.09486     32.4408284    71.4883905
  hsa-miR-507         −0.35197     −0.58369      0.70175     32.4408284   71.49526037
  hsa-miR-526b        0.030514     0.581534     −0.45904     32.4408284   71.53582005
  hsa-miR-496         0.850841     −0.05299     −0.59839     32.4408284   71.54645244
  hsa-miR-185         0.031791     0.573309     −0.45383     32.4408284   71.56623333
  hsa-miR-510         0.742406     −0.56788     −0.13089     32.4408284   71.60493642
  hsa-miR-452          0.02098     0.573449     −0.44582     32.4408284   71.81598617
  hsa-miR-127         −0.70529     −0.18458      0.6674      32.4408284    71.9211001
  hsa-miR-212         −0.61587     0.689795     −0.05545     32.4408284   72.13105619
  hsa-miR-26a         0.832095     -0.49388     −0.25366     32.4408284   72.20091674
  hsa-miR-383         −0.45492     0.701135     −0.18466     32.4408284   72.32614427
  hsa-miR-422a        −0.26395     0.806814     −0.40714     32.4408284    72.3764922
  hsa-miR-518c\*      0.001353     0.564767     −0.42459     41.3047974   72.53390646
  hsa-miR-196b        −0.67575     0.967093      −0.2185     41.3047974   72.53717424
  hsa-miR-150         0.050418     0.574385      −0.4686     41.3047974   72.67544996
  hsa-miR-302b\*      0.246155     −0.65687      0.30804     41.3047974   72.68497047
  hsa-miR-134         0.023544     0.583001     −0.45491     41.3047974   72.76553336
  hsa-miR-9\*          0.6188      −0.93082      0.23401     41.3047974   72.77217111
  hsa-miR-453         −0.74878     0.408178      0.25545     41.3047974   72.87972425
  hsa-miR-34a         −0.58065     −0.27546      0.64208     41.3047974   72.96315149
  hsa-miR-199a        −0.04344     0.698393     −0.49121     41.3047974   73.19135993
  hsa-miR-526c        0.000846     0.548959     −0.41235     41.3047974   73.26518389
  hsa-miR-515-3p      −0.73256     0.530075      0.15187     41.3047974   73.34759333
  hsa-miR-215         −0.03675     0.717886     −0.51085     41.3047974   73.34812817
  hsa-miR-181c         0.87805     −0.73324      −0.1086     41.3047974   73.58552846
  hsa-miR-302c\*       0.01393     0.540437     −0.41577     41.3047974   73.63892656
  hsa-miR-211          −0.0302     0.714761     −0.51342     41.3047974   73.73914691
  hsa-miR-515-5p      0.051513     0.532635     −0.43811     41.3047974   73.75924315
  hsa-miR-520g        −0.95069     −0.92546      1.40711     41.3047974   74.09075907
  hsa-miR-142-5p       −0.0799     0.677113     −0.44791     41.3047974   74.12613458
  hsa-miR-524\*       −0.00157     0.565716     −0.42311     41.3047974   74.15676194
  hsa-miR-324-5p      −0.21206     0.663358     −0.33847     41.3047974   74.23525626
  hsa-miR-432\*       −0.13292     0.678476     −0.40916     41.3047974   74.28848132
  hsa-miR-518f\*      −0.03101      0.5454      −0.38579     41.3047974   74.30610926
  hsa-miR-346         0.224671     0.480879     −0.52916     41.3047974   74.36735065
  hsa-miR-216         −0.45903      0.7177       −0.194      41.3047974   74.44567177
  hsa-miR-361          0.03535     0.671744     −0.53032     41.3047974   74.55343752
  hsa-miR-98          −0.60393     0.234364      0.27717     41.3047974   74.60460599
  hsa-miR-484         0.209461     0.738378     −0.71088     41.3047974   74.64404077
  hsa-miR-189         −0.80392     −0.68433      1.11619     41.3047974   75.05309477
  hsa-miR-126\*       0.027436     0.621051     −0.48637     41.3047974   75.09259849
  hsa-miR-545         0.351442     0.506327     −0.64333     41.3047974   75.16836638
  hsa-miR-302a         −0.0864     0.685513     −0.44934     41.3047974   75.20719598
  hsa-miR-432         −0.81081     0.255479      0.4165      41.3047974   75.25585407
  hsa-miR-224         −0.65873     −0.04749      0.52966     41.3047974    75.292015
  hsa-let-7i          −0.54415     −0.16195      0.52957     41.3047974   75.71872619
  hsa-miR-137         0.070381     0.650415      −0.5406     41.3047974   75.76579176
  hsa-miR-369-5p      0.749466     −0.27253      −0.3577     41.3047974   75.83285292
  hsa-miR-526a        −0.04561     0.52662      −0.36076     43.4773989   76.60067761
  hsa-miR-181b        0.487456     0.434359     −0.69136     43.4773989    76.6991424
  hsa-miR-365         −0.08579     0.600065     −0.38571     43.4773989   76.70911636
  hsa-miR-512-5p      0.584274     −0.53636     −0.03594     43.4773989   76.84890105
  hsa-miR-493-5p      −0.39502     −0.55077      0.70934     43.4773989   77.04222504
  hsa-miR-200a\*      −0.41277     −0.31389       0.545      43.4773989   77.05673199
  hsa-miR-509         0.610327     −0.27544     −0.25117     43.4773989   77.06179362
  hsa-miR-187         −0.53083     −0.10011      0.4732      43.4773989   77.28591448
  hsa-miR-214         −0.55444     0.28481       0.20223     43.4773989    77.6270228
  hsa-miR-193b         −0.5695     −0.27523      0.63355     44.7455322   77.84340704
  hsa-miR-18b         0.158782     −0.67872      0.38996     44.7455322   78.06910367
  hsa-miR-27a         −0.67425     −0.14205      0.61222     44.7455322   78.15702062

The list of 198 miRNAs were narrowed from 312 microRNA using a linear regression model and subsequently ranked by z-score test statistics. Local FDR evaluates false discoveries by assigning samples to random groups to test for statistical significance by chance. The relevance of FDR is determined using q-values, an analog of the p-value. The 21 top-ranked miRNAs have a q-value equal to 0%, meaning that it is highly unlikely for this miRNAs to be expressed differentially by chance among the three groups examined.

SZ =  schizophrenia; BD =  bipolar disorder; C =  controls.

10.1371/journal.pone.0048814.t003

###### SAM test of *Luminex* miRNA expression data for BD and C only.

![](pone.0048814.t003){#pone-0048814-t003-3}

  miRNA               q-value(%)    local FDR(%)
  ------------------ ------------- --------------
  hsa-miR-219              0        27.05850719
  hsa-miR-380-3p           0         28.5520989
  hsa-miR-499              0        29.39061044
  hsa-miR-497              0        29.86048144
  hsa-miR-149              0        30.16935542
  hsa-miR-501              0         32.7806583
  hsa-miR-29c              0        34.68749497
  hsa-miR-30e-3p      12.10826211   36.00723604
  hsa-miR-504         12.10826211   37.42550117
  hsa-miR-148a        12.10826211   39.79413767
  hsa-miR-520a        12.10826211   41.10693353
  hsa-miR-526b\*      12.10826211   43.98048662
  hsa-miR-15b         17.20647773   47.26654182
  hsa-miR-342         17.20647773   47.55108918
  hsa-miR-29b         17.20647773   49.13804596
  hsa-miR-409-5p      17.20647773   50.09111912
  hsa-miR-516-5p      17.20647773   50.61439857
  hsa-miR-520d\*      17.20647773   50.79672442
  hsa-miR-500         17.20647773   50.82589406
  hsa-miR-368         18.95206243   53.22108834
  hsa-miR-30e-5p      18.95206243   54.66652218
  hsa-miR-181c        18.95206243    55.4595906
  hsa-miR-26b         18.95206243   55.51339027
  hsa-miR-511         22.70299145   58.90676274
  hsa-miR-527         27.24358974   63.91589056
  hsa-miR-483         27.24358974    64.697843
  hsa-miR-544         27.24358974    65.0689104
  hsa-miR-518a-2\*    27.24358974   65.91311804
  hsa-miR-370         30.06189213   67.72976336
  hsa-miR-100         69.07664285   70.77603166
  hsa-miR-498         69.07664285   71.22258291
  hsa-miR-9\*         71.07023411   74.68821123
  hsa-miR-125a        71.07023411   76.54730008
  hsa-miR-502         72.64957265   78.54613247
  hsa-miR-26a         75.17482517   84.87201631
  hsa-miR-181d        77.26224393   94.90250066
  hsa-miR-510         77.26224393   95.66638517
  hsa-miR-512-5p      78.16485434       100
  hsa-miR-299-3p      78.16485434       100
  hsa-miR-142-3p      78.16485434       100
  hsa-miR-148b        82.00595701       100
  hsa-miR-376a        82.00595701       100
  hsa-miR-302a\*      82.00595701       100
  hsa-miR-503         82.00595701       100
  hsa-miR-202\*       82.00595701       100
  hsa-miR-376b        82.00595701       100
  hsa-miR-200a        84.15841584       100
  hsa-miR-542-3p      84.15841584       100
  hsa-miR-520e        84.15841584       100
  hsa-miR-516-3p      84.15841584       100
  hsa-miR-302b\*      84.54907162       100

The results show 7 miRNAs with q-values equal to 0%.

qPCR Analysis {#s2h}
-------------

Upon isolation and purification of RNA from exosome-containing pellets as above, the RNA concentration of each sample tested ([Table 1](#pone-0048814-t001){ref-type="table"}) was calculated using *Agilent Bioanlyzer 2100* data. 20 ng of RNA was used to synthesize cDNA in a 20 ul reaction volume employing *Exiqon mIRCURY LNA* microRNA PCR Universal cDNA Synthesis Kit (Denmark). Quantitative PCR (qPCR) reactions for miRNAs of interest were performed according to the same manufacturer's protocol. Briefly, cDNA was diluted to a final concentration of 0.1 ng/ul, added to a primer set generated by *Exiqon* and PCR SYBR Green Master Mix by the same manufacturer, and run for 40 cycles on a *Bio-Rad iCycler*. To obtain a change in CT (Delta-CT) for each miRNA of interest we needed to have an internal control in every sample. *Luminex* data as well as preliminary qPCRs established that miR-423 had a stable and robust expression in the samples tested ([Table S1](#pone.0048814.s004){ref-type="supplementary-material"}). Thus, all the analyzed samples were run in duplicates for each miRNA of interest and for miR-423 as a reference [@pone.0048814-Liang1]--[@pone.0048814-Meyer1], (<http://www.exiqon.com/ls/Documents/Scientific/miRNA-qPCR-guidelines.pdf>) in a minimum of three separate plates. In each plate, the average CT value for miR-423 was subtracted from average CT value for a given miRNA of interest to obtain a value of change in CT (Delta-CT) for every sample. Student's t-tests on control and BD and on control and SZ Delta-CT values were performed using *Graph Pad Prism 5*.

Results {#s3}
=======

Exosomal Marker Identification in Exosome-containing Pellets from Postmortem Human Prefrontal Cortex {#s3a}
----------------------------------------------------------------------------------------------------

To confirm the presence of exosomes in our pellet-preparations from postmortem human frozen BA9 cortices, we examined the morphology and antigenicity of the pellet content ([Figure 1](#pone-0048814-g001){ref-type="fig"}). On electron microscopy, membrane-bound vesicles with diameters of 70--90 nm were immunoreactive for antigens commonly found in exosomes, CD63 and GAPDH ([Figure 1A and B](#pone-0048814-g001){ref-type="fig"}). Next, we evaluated the efficiency of our exosomal extractions from brain tissue. Western blot analysis revealed the presence of flotillin-2, protein commonly associated with exosomal membrane [@pone.0048814-Strauss1], in both BA9 pellets and in exosomes-containing pellets from the medium of cultured H4 cells ([Figure 1C](#pone-0048814-g001){ref-type="fig"}). The exosomal extraction procedures depleted flotillin-2 from the supernatants ([Figure 1C](#pone-0048814-g001){ref-type="fig"}).

![Characterization of exosome-containing pellets from human brain tissue.\
Electron microscopy of exosomal extractions from BA9 cortices demonstrates the presence of microvesicles (∼70--100 nm in diameter). Upon immuno-gold labeling procedure with antibodies against CD63 (A; additional negative staining highlights membrane of the vesicle) and GAPDH (B), the microvesicles reveal the presence of exosome-associated antigens. Bars indicate 100 nm. Comparison of exosomal extraction procedure products from BA9 cortices and H4 cell-culture reveals similar outcomes in Western blot. Supernatant of BA9 exosome-containing pellets (lane 1), supernatant of H4 exosome-containing pellets (lane 2), BA9 exosome-containing pellets reconstituted in PBS (lane 3), and of H4 exosome-containing pellets reconstituted in PBS (lane 4), show robust presence of exosomal marker flotillin-2 in the pellets, but not in the supernatants (C).](pone.0048814.g001){#pone-0048814-g001}

Luminex miRNA Expression Analysis in Exosome-containing Pellets from SZ and BD Patients Suggest Differential Expression of a Subset of miRNAs in Comparison to Controls {#s3b}
-----------------------------------------------------------------------------------------------------------------------------------------------------------------------

*Luminex* miRNA expression data in exosome-containing pellets from prefrontal (BA9) gray matter of 8 SZ patients (SZ 1--8), 6 BD patients (BD 1--6), and 6 controls (C 1--6) ([Table 1](#pone-0048814-t001){ref-type="table"}) were submitted to Student's t-test. These data reveal several significantly differentially expressed miRNAs in either BD or SZ, or both in comparison to controls. Bonferroni Step-down Holm Correction was then applied to correct for multiple comparisons [@pone.0048814-Holm1]. This correction resulted in the absence of significantly differentially expressed miRNAs in BD samples, while the expression of only three miRNAs (miR- 31, -33, and -96) was significantly enhanced in SZ samples in comparison to controls and to BD ([Table S1](#pone.0048814.s004){ref-type="supplementary-material"}). In an alternative statistical approach towards identification of miRNAs differentially expressed in the three groups examined, we submitted raw *Luminex* miRNA expression data to Significance Analysis of Microarrays (SAM) program [@pone.0048814-Tusher1],[@pone.0048814-Efron1] ([Table 2](#pone-0048814-t002){ref-type="table"}). SAM ranked the expressions of examined miRNA expression using z-scores ([Table 2](#pone-0048814-t002){ref-type="table"}). For the 21 top-ranked miRNAs, Prediction Analysis of Microarrays (PAM) [@pone.0048814-Tibshirani1]-- derived q-value was 0% ([Figure 2](#pone-0048814-g002){ref-type="fig"}). We next examined how the expression of these 21 top-ranked miRNAs might influence the clustering of our samples. Surprisingly, the dendrogram from the clustering analysis [@pone.0048814-Tibshirani1] ([Figure 3](#pone-0048814-g003){ref-type="fig"}) suggests that the expression the 21 top-ranked miRNAs segregated SZ samples from BD samples and controls, leaving BD samples and controls undifferentiated from one another. In order to remove the influence of SZ group on the ranking system, the SAM program was run again for BD and control groups only ([Table 3](#pone-0048814-t003){ref-type="table"}) and yielded 7 miRNAs with q- value of 0% ([Table 3](#pone-0048814-t003){ref-type="table"}). This group of miRNAs, however, had a rather limited ability to segregate BD samples from controls (cluster dendrogram not shown). These results prompted us to submit the entire *Luminex* data to a PAM-derived misclassification rate analysis to determine if the miRNA expression values of each sample in a group have a reliable predictive power, i.e. if they can serve as biomarkers for a given group [@pone.0048814-Tibshirani2]--[@pone.0048814-Tibshirani1]. The misclassification rate was 0 for the SZ group ([Figure 4](#pone-0048814-g004){ref-type="fig"}), indicating that: a) the examined miRNA expressions were tightly grouped in SZ as previously indicated by the cluster dendrogram (see [Figure 3](#pone-0048814-g003){ref-type="fig"}); and b) the expression values of a very small number of miRNAs can assign an SZ sample to its correct group. The control samples had most variable miRNA expression levels associated with high misclassification rate regardless of how many miRNAs were evaluated ([Figure 4](#pone-0048814-g004){ref-type="fig"}). Finally, [Figure 4](#pone-0048814-g004){ref-type="fig"} shows that the misclassification rate for BD samples is dependent on the number of miRNAs evaluated: if ∼13--16 miRNAs are taken into account, BD samples separate well from controls and reach zero misclassification rate that is characteristic of SZ samples ([Figure 4](#pone-0048814-g004){ref-type="fig"}).

![Median and 90th percentile of False Discovery Rates (FDR) in order left-to-right of threshold value and number of statistically significant results for all three groups (C, BD, and SZ).\
The Y-axis is an estimate of the percentage of false positives. High-ranked miRNA (at the left) have a low rate of false positives, while lower-ranked miRNA (moving toward the right) have higher rates of false positives.](pone.0048814.g002){#pone-0048814-g002}

![Hierarchical clustering analysis of top 21 ranked miRNAs from FDR analysis.\
Correlation coefficient (cc) was generated to assess the relationship between the expression values of each sample and the rest of the samples (see Methods). The coefficient is 1 if their expression profiles are highly similar and 0 if their expression profiles are highly divergent. The clustering graph is built so that the samples with similar expression patterns are clustered at the bottom while more differential patterns are at the top of the graph.](pone.0048814.g003){#pone-0048814-g003}

![Misclassification rate analysis.\
(A) Controls (red) have the most variable miRNA expression. The expression data have less variability in BD (green) and the least in SZ (blue; misclassification rate  = 0), resulting in stronger predictive power within their respective clinical groups.](pone.0048814.g004){#pone-0048814-g004}

Covariate Analysis: the Effect of Medications on SAM Results {#s3c}
------------------------------------------------------------

The clinical information accompanying our samples failed to provide sufficient data to control for tobacco, alcohol or recreational drug consumption ([Table S4](#pone.0048814.s007){ref-type="supplementary-material"}), while the information of prescribed medications ([Table 4](#pone-0048814-t004){ref-type="table"}) was well defined. The cases were marked if the patients took at least one medication from the seven drug classes constructed on the basis of the common mechanism(s) underlying drug effect (A-G; [Table 5](#pone-0048814-t005){ref-type="table"}). Since a standard error is used to generate a covariate effect, only drug classes with at least three case-subjects taking a drug and three case-subjects not taking a drug could be evaluated as covariates. Thus, only drug classes A (antipsychotics used in SZ only), B (neurotransmitter receptor-site binders used in both BD and SZ), and C (sedatives, hypnotics, anticonvulsants and analgesics used in both BD and SZ) could be controlled for.

10.1371/journal.pone.0048814.t004

###### Medications (grouped in classes A-G) prescribed to subject cases for psychiatric and neurological symptoms.
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  Case         Medications prescribed for psychiatric and neurological symptoms, daily mg     A   B   C   D   E   F   G
  --------- -------------------------------------------------------------------------------- --- --- --- --- --- --- ---
  SZ1                       Levomepromazine 100, Haloperidol 10, Diazepam 5                   X       X              
  SZ2              Amisulpride 200, Quetiapine 200, Clonazepam 0.5, Oxcarbazepine 300             X   X              
  SZ3         Haloperidol 5, Olanzapine 10, Lorazepam 1, Clomethiazole 192, Imipramine 50     X   X   X              
  SZ4                Lormetazepam 1, Olanzapine 10, Lorazepam 1, Clomethiazole 192                X   X              
  SZ5                                        Olanzapine 15                                        X                  
  SZ6                                        Phenitoine 100                                           X              
  SZ7                   Clozapine 400, Trazadone 50, Haloperidol 5, Lorazepam 1               X   X   X               X
  SZ8                                             None                                                               
  BD1                  Lithium 400, Methylphenidate 20, Diazepam 10, Oxazepam 20                      X   X   X      
  BD2                       Lithium 400, Quetiapine 25, Midazolam (amount?)                       X   X   X          
  BD3        Risperidone 1.5, Gabapentin 600, Nefazodone 600, Topiramate 75, Ziprasidone 20       X   X           X  
  BD4                Valproic acid 1500, Paroxetine 20, Clonazepam 4, Olanzapine 10               X   X           X  
  BD5                                      Lithium (amount?)                                              X          
  BD6                              Valproic acid 1000, Quetiapine 125                             X       X          
  BD7                                       Moclobemide 300                                                   X      
  BD8                                  Dexamphetamine sulphate 5                                              X      
  BD9                                      Tranylcypromine 60                                                 X      
  C1--C13                                         None                                                               

SZ =  schizophrenia; BD =  bipolar disorder; C =  controls.

10.1371/journal.pone.0048814.t005

###### Classes (A--G) encompassing the medications in [Table 4](#pone-0048814-t004){ref-type="table"}.
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  Class                    Description of medication class                    Prescribed medicationfrom the class                                                        Effects
  ------- ------------------------------------------------------------------ ------------------------------------- --------------------------------------------------------------------------------------------------------------------
  A                       Antipsychotics specifically for SZ                            Levomepromazine             Phenothiazine Group; dopamine, adrenalin, histamine, acetylcholine and serotonin antagonist; antipsychotic effects
  A                       Antipsychotics specifically for SZ                              Haloperidol                               dopamine antagonist; effects similar to Phenothiazine group; antipsychotic effects
  B            Neurotransmitter receptor- site binders usedin BD and SZ                   Olanzapine                         dopamine, serotonin, adrenergic antagonist with antihistaminic effect; antipsychotic properties
  B            Neurotransmitter receptor- site binders usedin BD and SZ                    Clozapine                         dopamine, serotonin, adrenergic antagonist with antihistaminic effect; antipsychotic properties
  B            Neurotransmitter receptor- site binders usedin BD and SZ                   Quetiapine                         dopamine, serotonin, adrenergic antagonist with antihistaminic effect; antipsychotic properties
  B            Neurotransmitter receptor- site binders usedin BD and SZ                   Amisulpride                                          dopamine and serotonin antagonist; antipsychotic properties
  B            Neurotransmitter receptor- site binders usedin BD and SZ                   Risperidone                        dopamine, serotonin, adrenergic antagonist with antihistaminic effect; antipsychotic properties
  B            Neurotransmitter receptor- site binders usedin BD and SZ                   Ziprasidone                        dopamine, serotonin, adrenergic antagonist with antihistaminic effect; antipsychotic properties
  C        Sedatives, hypnotics, anticonvulsants and analgesicsin BD and SZ                Diazepam                                Benzodiazipines, i.e. GABA agonists; sedative, hypnotic, with anticonvulsant effects
  C        Sedatives, hypnotics, anticonvulsants and analgesicsin BD and SZ               Clonazepam                               Benzodiazipines, i.e. GABA agonists; sedative, hypnotic, with anticonvulsant effects
  C        Sedatives, hypnotics, anticonvulsants and analgesicsin BD and SZ                Lorazepam                               Benzodiazipines, i.e. GABA agonists; sedative, hypnotic, with anticonvulsant effects
  C        Sedatives, hypnotics, anticonvulsants and analgesicsin BD and SZ                Oxazepam                                Benzodiazipines, i.e. GABA agonists; sedative, hypnotic, with anticonvulsant effects
  C        Sedatives, hypnotics, anticonvulsants and analgesicsin BD and SZ                Midazolam                               Benzodiazipines, i.e. GABA agonists; sedative, hypnotic, with anticonvulsant effects
  C        Sedatives, hypnotics, anticonvulsants and analgesicsin BD and SZ              Clomethiazole                                        GABA agonist; sedative, hypnotic, with anticonvulsant effects
  C        Sedatives, hypnotics, anticonvulsants and analgesicsin BD and SZ              Oxcarbazepin                              ion, mostly sodium, channel stabilizer; anticonvulsant and mood stabilizing effects
  C        Sedatives, hypnotics, anticonvulsants and analgesicsin BD and SZ                Phenitoin                                                 sodium channel stabilizer, anticonvulsant effect
  C        Sedatives, hypnotics, anticonvulsants and analgesicsin BD and SZ               Gabapentin                                                GABA agonist; anticonvulsant and analgesic effects
  C        Sedatives, hypnotics, anticonvulsants and analgesicsin BD and SZ               Topiramate                                                     mechanism unclear; anticonvulsant effect
  D                       Antipsychotics specifically for BD                             Valproic acid                                      GABA effects enhancer; anticonvulsant and mood-stabilizing effects
  D                       Antipsychotics specifically for BD                                Lithium                                                    mechanism unclear; mood-stabilizing effects
  E                          Psycho-stimulants used in BD                                 Moclobemide                                              monoamine oxidase inhibitors; antidepressant effects
  E                          Psycho-stimulants used in BD                               Tranylcypromine                                            monoamine oxidase inhibitors; antidepressant effects
  E                          Psycho-stimulants used in BD                               Methylphenidate                                                     dopamine enhancer, psychostimulant
  E                          Psycho-stimulants used in BD                               Dexamphetamine                                                               psychostimulant
  F                  Serotonin and adrenergic antagonists for BD                          Nefazodone                                           serotonin and adrenergic antagonist; antidepressant effects
  F                  Serotonin and adrenergic antagonists for BD                          Paroxetine                                       serotonin re-uptake inhibitor; antidepressant and anxiolytic effects
  G                          Serotonin antagonist for SZ                                   Trazodone                          serotonin antagonist and reuptake inhibitor, antidepressant, anxiolytic, and sedative effects

SZ =  schizophrenia; BD =  bipolar disorder.

In a simple format of covariate adjustment [@pone.0048814-Ghosh1] the effects of multiple independent variables are added together in a linear regression model. To guard against Type I errors, we designed a model to adjust for covariates using the SAM program. SAM was rerun to compare case subjects taking a specific drug class medication against case subjects not taking it, and a list of covariate effects for drug classes A--C was derived for top-ranked miRNA in the study ([Table 6](#pone-0048814-t006){ref-type="table"}). Those effects were then subtracted from the original z-scores ([Tables 2](#pone-0048814-t002){ref-type="table"} and [3](#pone-0048814-t003){ref-type="table"}) and p-values were added to demonstrate the effects of the covariate on significance ([Tables 7](#pone-0048814-t007){ref-type="table"} and [8](#pone-0048814-t008){ref-type="table"}).

10.1371/journal.pone.0048814.t006

###### Covariate effects of medications on highly-ranked miRNAs in SAM (top-21 in [Table 2](#pone-0048814-t002){ref-type="table"} and top-12 in [Table 3](#pone-0048814-t003){ref-type="table"}).
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  miRNA              Class A      Class B      Class C
  ---------------- ------------ ------------ ------------
  hsa-miR-31        −0.5474735   0.0027362   
  hsa-miR-33        0.6342707    −0.3112329   0.9637398
  hsa-miR-96         0.040926    0.5554684   
  hsa-miR-28        1.1396825    1.0107414   
  hsa-miR-30e-5p    0.3379079                
  hsa-miR-199a\*    −0.8762626               
  hsa-miR-501       0.0812317    −0.167766    −0.6013733
  hsa-miR-504       0.2946595    −0.1356475   −0.3858902
  hsa-miR-15b       −0.1307195               
  hsa-miR-29c        −0.1678     0.3820155    0.1279756
  hsa-miR-455       −0.2162923   −0.2365768  
  hsa-miR-380-3p    −0.1295169   −0.2513642   −0.2837673
  hsa-miR-323       0.0956179    −0.3292096  
  hsa-miR-527       0.3199353    −0.3980191   −0.4156484
  hsa-miR-93        0.8926459    0.8342627    1.4247242
  hsa-miR-32        −0.3081563               
  hsa-miR-20b       −0.3025591               
  hsa-miR-516-5p    0.1006308    −0.2462411   −0.4384718
  hsa-miR-92        1.5916982                 1.9080176
  hsa-miR-30a-3p    0.2072069                
  hsa-miR-497       0.1045716    −0.2486034    0.036478
  hsa-miR-219       0.3630727    −0.2988121  
  hsa-miR-499       −0.0609767   −0.3046793   −0.2561058
  hsa-miR-149        0.654253    −0.2538624    0.04254
  hsa-miR-30e-3p    0.4068861    −0.0672197    0.11598
  hsa-miR-148a                               
  hsa-miR-520a      −0.0963095   −1.5626633  
  hsa-miR-526b\*    0.3595811     0.594503   

10.1371/journal.pone.0048814.t007

###### Top-ranked miRNAs from [Table 2](#pone-0048814-t002){ref-type="table"}, adjusted for covariate effects of medications (classes A, B, C, and B+C).

![](pone.0048814.t007){#pone-0048814-t007-7}

  miRNA             SZ score (z-score from SAM)    p-value     Class A covariate adjust     p-value     Class B covariate adjust   p-value   Class C covariate adjust   p-value   Classes B+C covariate adjust    p-value
  ---------------- ----------------------------- ------------ -------------------------- ------------- -------------------------- --------- -------------------------- --------- ------------------------------ ------------
  hsa-miR-31                  3.55283             **0.0007**           4.10031            **0.00009**           3.55010            0.00073           3.55283            0.00072              3.5501              **0.0007**
  hsa-miR-33                  3.10046             **0.0032**           2.46619            **0.01906**           3.41170            0.00118           2.13672            0.04069              2.4480              **0.0199**
  hsa-miR-96                  2.98240             **0.0046**           2.94147            **0.00527**           2.42693            0.02099           2.98240            0.00467              2.4269              **0.0210**
  hsa-miR-28                  2.31611             **0.0272**           1.17643              0.19970             1.30537            0.17017           2.31611            0.02729              1.3054                0.1702
  hsa-miR-30e-5p              2.37744             **0.0236**           2.03954            **0.04985**           2.37744            0.02363           2.37744            0.02363              2.3774              **0.0236**
  hsa-miR-199a\*              2.21841             **0.0340**           3.09467            **0.00332**           2.21841            0.03406           2.21841            0.03406              2.2184              **0.0341**
  hsa-miR-501                −1.38651               0.1525             −1.46774             0.13587             −1.21874           0.18983           −0.78514           0.29312             −0.6174                0.3297
  hsa-miR-504                −1.26857               0.1784             −1.56323             0.11756             −1.13292           0.20999           −0.88268           0.27022             −0.7470                0.3018
  hsa-miR-15b                 1.94092               0.0606             2.07164            **0.04666**           1.94092            0.06066           1.94092            0.06066              1.9409                0.0607
  hsa-miR-29c                −1.25599               0.1812             −1.08819             0.22068             −1.63801           0.10430           −1.38397           0.15311             −1.7660                0.0839
  hsa-miR-455                 1.93342               0.0615             2.14972            **0.03957**           2.17000            0.03788           1.93342            0.06154              2.1700              **0.0379**
  hsa-miR-380-3p             −0.78517               0.2931             −0.65565             0.32178             −0.53381           0.34597           −0.50140           0.35182             −0.2500                0.3867
  hsa-miR-323                 1.79862               0.0791             1.70300              0.09357             2.12783            0.04147           1.79862            0.07915              2.1278              **0.0415**
  hsa-miR-527                −1.15943               0.2037             −1.47937             0.13356             −0.76141           0.29855           −0.74378           0.30254             −0.3458                0.3758
  hsa-miR-93                  1.59984               0.1109             0.70719              0.31068             0.76558            0.29760           0.17512            0.39287             −0.6591                0.3210
  hsa-miR-32                  1.70564              0.09315             2.01380            **0.05252**           1.70564            0.09315           1.70564            0.09315              1.7056                0.0931
  hsa-miR-20b                 1.87742              0.06847             2.17998            **0.03706**           1.87742            0.06847           1.87742            0.06847              1.8774                0.0685
  hsa-miR-516-5p             −0.84614              0.27890             −0.94677             0.25484             −0.59990           0.33325           −0.40767           0.36713             −0.1614                0.3938
  hsa-miR-92                  1.56396              0.11743             −0.02774             0.39879             1.56396            0.11743           −0.34406           0.37601             −0.3441                0.3760
  hsa-miR-30a-3p              1.67931              0.09740             1.47210              0.13500             1.67931            0.09740           1.67931            0.09740              1.6793                0.0974
  hsa-miR-497                −0.56728              0.33965             −0.67185             0.31834             −0.31867           0.37919           −0.60376           0.33247             −0.3551                0.3746

The significance of results for miRNAs 31, 33, 96, 30e-5p, and 199a\* (bold) was preserved (see [Table 2](#pone-0048814-t002){ref-type="table"}), while miRNAs 15b, 455, 32, and 20b acquire significance (bold) after the adjustment for the drug class A (antipsychotics used in SZ only). After the adjustment for drug classes B (neurotransmitters receptor-site binders) and C (sedatives, hypnotics, anticonvulsants and analgesics) drug classes, the significance for miRNAs 31, 33, 96, 30e-5p, and 199a\* (bold) was again preserved (see [Table 2](#pone-0048814-t002){ref-type="table"}) while miR-455 acquired significance together with miR-323 (bold).

SZ =  schizophrenia.

10.1371/journal.pone.0048814.t008

###### Top-ranked miRNAs from [Table 3](#pone-0048814-t003){ref-type="table"}, adjusted for covariate effects of medications (classes B, C, and B+C).
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  miRNA             BD score (z-score from SAM)    p-value     Class B covariate adjust   p-value   Class C covariate adjust   p-value   Classes B+C covariate adjust    p-value
  ---------------- ----------------------------- ------------ -------------------------- --------- -------------------------- --------- ------------------------------ ------------
  hsa-miR-219                 −2.8237             **0.0074**           −2.8237            0.0074            −3.1225            0.0030              −3.1225              **0.0030**
  hsa-miR-380-3p              −2.2933             **0.0287**           −2.0419            0.0496            −2.0095            0.0529              −1.7581                0.0850
  hsa-miR-499                 −2.2226             **0.0337**           −1.9179            0.0634            −1.9665            0.0576              −1.6618                0.1002
  hsa-miR-497                 −2.1947             **0.0358**           −1.9460            0.0600            −2.2311            0.0331              −1.9825                0.0558
  hsa-miR-149                 −2.1785             **0.0371**            −1.924            0.0625            −2.2211            0.0338              −1.9672                0.0576
  hsa-miR-501                 −2.0751             **0.0463**           −1.9073            0.0647            −1.4737            0.1346              −1.3059                0.1700
  hsa-miR-29c                 −2.0161             **0.0522**           −2.3981            0.0224            −2.1440            0.0400              −2.5260              **0.0164**
  hsa-miR-30e-3p              −1.9787               0.0563             −2.0274            0.0444            −2.0947            −1.9115              0.0641              **0.0510**
  hsa-miR-504                 −1.9404               0.0607             −1.4189            0.1191            −1.5545            −1.8048              0.0782                0.1457
  hsa-miR-148a                −1.8790               0.0682             −1.8790            0.0682            −1.8790            −1.8790              0.0682                0.0682
  hsa-miR-520a                −1.8457               0.0726             −0.2830            0.0726            −1.8457            −0.2830              0.3832                0.3832
  hsa-miR-526b\*              −1.7745               0.0826             −2.3691            0.0826            −1.7745            −2.3691              0.0241              **0.0241**

The consideration of combined effects of B and C drug classes heightened the significance of the results for miRNAs 219 and 29c (bold; see [Table 3](#pone-0048814-t003){ref-type="table"}), while miRNA 30e-3p and 526b\* (bold) acquired significance.

BD =  bipolar disorder.

When adjusted for drug class A (antipsychotics used in SZ only), the significance of results for miRNAs 31, 33, 96, 30e-5p, and 199a\* was preserved, while miRNAs 15b, 455, 32, and 20b acquire significance ([Table 7](#pone-0048814-t007){ref-type="table"}, see also [Table 2](#pone-0048814-t002){ref-type="table"}). After the adjustment for B (neurotransmitters receptor-site binders) and C (sedatives, hypnotics, anticonvulsants and analgesics) drug classes in SZ subjects, the significance for miRNAs 31, 33, 96, 30e-5p, and 199a\* was still preserved while miR-455 (again) acquired significance together with miR-323 ([Table 7](#pone-0048814-t007){ref-type="table"}, see also [Table 2](#pone-0048814-t002){ref-type="table"}). In BD subjects, the consideration of combined effects of B and C drug classes heightened the significance of the results for miRNAs 219 and 29c while miRNA 30e-3p and 526b\* acquired significance ([Table 8](#pone-0048814-t008){ref-type="table"}, see also [Table 3](#pone-0048814-t003){ref-type="table"}). Importantly, Wilcoxon test also indicated the expression of miRNAs 219 and 526b to be significantly different in BD cases in comparison to controls, but failed to discover miRNA 29c ([Table S3](#pone.0048814.s006){ref-type="supplementary-material"}; see Discussion).

Finally, while effects related to gender were not relevant to this study due to a male dominated cohort, we did consider the ages of our cases ([Table 1](#pone-0048814-t001){ref-type="table"}). Although the SZ group of cases is on average older than BD and control groups, no significant difference in age between groups exists ([Table S5](#pone.0048814.s008){ref-type="supplementary-material"}).

qPCR Analysis Confirms Differential Expression of miR-497 in SZ, and miR-29c in BD Samples in Comparison to Controls {#s3d}
--------------------------------------------------------------------------------------------------------------------

To verify microarray data for miRNAs that may be differentially expressed in our three analyzed groups, controls, BD, and SZ, we performed a series of qPCR experiments. The primers for the following miRNAs worked in reactions with cDNA derived from each of our samples available for analysis: miR-31, -15b, -29c, -497, -219, and -149. These miRNAs were among the highest ranked according to the likelihood to be differentially expressed in both SZ and BD (miR-31, -15b, -29c, and -497; [Table 2](#pone-0048814-t002){ref-type="table"}), or just BD (miR-219 and -149; [Table 3](#pone-0048814-t003){ref-type="table"}). To further test the reproducibility of our data we used additional BD and additional control cases that became available through brain banks and BMC autopsy service ([Table 1](#pone-0048814-t001){ref-type="table"}): SZ 1--6 (same as in *Luminex* experiment), BD 5--9 (three new samples), and C 6--13 (seven new samples). As shown in [Table 9](#pone-0048814-t009){ref-type="table"} and [Figure 5](#pone-0048814-g005){ref-type="fig"}, qPCR analyses confirmed miR-29c to be significantly differentially expressed (2.77 fold increased) in the examined BD samples, and miR-497 in SZ samples (2.35 fold increased) in comparison to controls.

![In comparison to controls, the expression of miR-29c and miR-497 is significantly increased in BD and SZ samples, respectively.\
Average exosomal RNA extracted from BA9 cortices of BD samples show a 2.77 fold increase of miR-29c in comparison to controls (A). SZ samples reveal 2.35 fold increase of miR-497 when compared to controls (B). Error bars indicate S.E.M.](pone.0048814.g005){#pone-0048814-g005}

10.1371/journal.pone.0048814.t009

###### Student's t-test comparison of qPCR Delta-CT.
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  miRNA          p-value, BD   Significant fold change   p-value, SZ   Significant fold change
  ------------- ------------- ------------------------- ------------- -------------------------
  hsa-miR-15b      0.6971                                  0.7906     
  hsa-miR-29c      0.0237               2.77                0.501     
  hsa-miR-31        0.426                                  0.3699     
  hsa-miR-149       0.591                                  0.5011     
  hsa-miR-219      0.8723                                  0.4059     
  hsa-miR-497      0.1969                                  0.0026               2.35

miR-29c expression is significantly increased in BD samples, and miR-497 in SZ samples.

BD =  bipolar disorder; SZ =  schizophrenia.

Discussion {#s4}
==========

While genetic component has been extensively researched in BD and SZ patients, the biological markers for these diseases have proven remarkably elusive. The putative susceptibility genes in both BD and SZ regulate cell-signaling [@pone.0048814-Harrison1]--[@pone.0048814-Owen1]. This study analyzed the expression of miRNAs found in exosomes ([Figure 1A and B](#pone-0048814-g001){ref-type="fig"}), signaling vesicles capable of cell-to-cell transfer of miRNAs, in the prefrontal cortices of patients diagnosed with either BD or SZ and of individuals with no mental illnesses. Standard statistical analysis (Student's t-test with Bonferroni Step Down/Holm correction) of the results of *Luminex* oligonucleotide- based screen for the expression of 312 miRNAs revealed only three miRNAs differentially expressed in SZ in comparison to BD and control samples ([Table S1](#pone.0048814.s004){ref-type="supplementary-material"}). While these three miRNAs (miR-31, -33, and -96) were also most highly ranked in a z-score based SAM, an additional 18 miRNAs were suggested to have truly differential expression ([Table 2](#pone-0048814-t002){ref-type="table"}). Accordingly, the expression values of about 21 miRNAs were not false discoveries in a three-way comparison ([Figure 2](#pone-0048814-g002){ref-type="fig"}). These 21 miRNAs distinguished SZ but not BD samples from controls relatively well ([Figure 3](#pone-0048814-g003){ref-type="fig"}). Upon elimination of the distinctive influence of SZ samples in the three-way comparison ([Table 2](#pone-0048814-t002){ref-type="table"}), the short list of most differentially expressed miRNA in BD compared to controls ([Table 3](#pone-0048814-t003){ref-type="table"}) still featured several of the original top 21-ranked miRNAs. The covariate adjustment for the medications used by some of the subject cases ([Tables 4](#pone-0048814-t004){ref-type="table"} and [5](#pone-0048814-t005){ref-type="table"}), had nominal effects on significance of differential miRNA expression in the SZ group, while in the BD group the difference in the expression of miR-30e-3p, -219 and -29c attained heightened significance ([Tables 6](#pone-0048814-t006){ref-type="table"}--[8](#pone-0048814-t008){ref-type="table"}). To verify the microarray data, we performed qPCR analysis of the selected miRNAs in a partially new set of samples. Two miRNAs were confirmed to have significantly altered expression: in comparison to controls, the expression of miR-497 and miR-29c were significantly higher in SZ samples and BD samples, respectively ([Table 9](#pone-0048814-t009){ref-type="table"}).

Our study has several novel and important findings. While exosomal content has been intensively studied in human diseases ever since the report of Valadi et al. in 2007 [@pone.0048814-Valadi1], we demonstrated here for the first time that exosomal miRNAs could be obtained from frozen postmortem brain tissue. On electron microscopy our PFC- derived exosome-containing pellets showed membrane bound vesicles within the range of the reported size of exosomes [@pone.0048814-Nilsson1] ([Figure 1A and B](#pone-0048814-g001){ref-type="fig"}). In addition to the identification by size, shape, and miRNA content (intracellular micro-vesicles of similar size, e.g. lysosomes, do not contain miRNAs), we demonstrated a robust signal for CD63 and GAPDH in the micro-vesicles extracted from the human PFC ([Figure 1A and B](#pone-0048814-g001){ref-type="fig"}). According to Mathivanan and Simpson (2009) [@pone.0048814-Mathivanan1] exosomes from different sources have varying sets of protein markers on their surface, with CD63 being the second most, and GAPDH being the fourth most commonly reported exosomal antigen. Finally, our exosome-containing pellets were enriched with exosomal marker flotillin-2 [@pone.0048814-Strauss1] on Western blots, similar to the pellets from the medium of cultured cells ([Figure 1C](#pone-0048814-g001){ref-type="fig"}). Having insight into the cortical exosomal miRNA content may be of particular importance because exosomes are released into the CSF, and thus accessible for evaluation in living patients [@pone.0048814-Street1]. A recent study identified a substantial number of miRNAs exclusively or predominantly expressed in CSF [@pone.0048814-Gallego1]. Comparing the data from brain tissue with CSF will indeed require clinical investigation since postmortem brain depositories do not currently have sufficient number of samples and/or amount of CSF from neuropsychiatric patients. So far, the search for specifically altered miRNA expression in peripheral blood mononuclear cells (PBMCs) in SZ yielded diverse results [@pone.0048814-Lai1], [@pone.0048814-Gardiner1]. Three miRNAs were found to be differentially expressed in PBMCs as well as in PFC (BA46) of SZ patients [@pone.0048814-Lai1]--[@pone.0048814-Santarelli1].

The second novel and important feature of our investigation lies in the fact that our statistical analyses pointed to both differences and similarities between the miRNA expression changes in SZ and BD samples in comparison to control samples. The SAM top 21- ranked miRNAs ([Table 2](#pone-0048814-t002){ref-type="table"}, [Figure 2](#pone-0048814-g002){ref-type="fig"}) had the ability to separate SZ samples, but not BD samples from the controls ([Figure 3](#pone-0048814-g003){ref-type="fig"}). This finding is directly connected to the suggested inherent differences in the variability of miRNA expression values in control samples in the three analyzed groups of samples, illustrated by the misclassification error rate analysis ([Figure 4](#pone-0048814-g004){ref-type="fig"}). The high variability of miRNA expression values in control samples represents perhaps a defining feature - the agility of the cortical transcriptional regulation in the absence of mental disease.

Initial statistical analysis revealed three miRNAs (miR-31, -33, and -96) differentially regulated in SZ samples ([Table S1](#pone.0048814.s004){ref-type="supplementary-material"}). Of those three, miR-33 was previously reported among misexpressed miRNAs in PFCs of both SZ and BD individuals [@pone.0048814-Moreau1]. Since we performed qPCR for additional miRNAs that were likely to be differentially expressed in SZ and BD samples according to SAM ([Tables 2](#pone-0048814-t002){ref-type="table"} and [3](#pone-0048814-t003){ref-type="table"}), we found significantly increased miR-497 expression in exosome-containing pellets from PFCs of SZ patients ([Table 9](#pone-0048814-t009){ref-type="table"}). Perkins et al. (2007) [@pone.0048814-Perkins1] reported 16 miRNAs to be differentially expressed in PFCs of SZ subjects, one being miR-195. Both miR-195 and -497 belong to the well-studied miR-15/107 gene family. miR-15/107 miRNAs share most of their targets and are implicated in the pathogenesis of neoplasms, neurodegenerative diseases and heart disease [@pone.0048814-Finnerty1]. Importantly, the up-regulation of these miRNAs expected to affect cortical gene expressions, has been reported in SZ [@pone.0048814-Beveridge2]. Interestingly, miR-497 was also found to promote ischemic neuronal death by negatively regulating anti-apoptotic proteins, bcl-2 and bcl-w [@pone.0048814-Yin1]. Three more miRNAs from our SAM top 21-ranked miRNAs were on the list of significantly down-regulated miRNAs in SZ by Perkins and colleagues [@pone.0048814-Perkins1]: miR-92, -20b, and -30e. miR-92 and -20b belong to miR-17-92 cluster known to be a potent oncogene [@pone.0048814-Conkrite1]. Potentially pertinent for SZ pathobiology, miR-92 has also been suggested to developmentally regulate neuronal K(+)Cl(−) co-transporter 2 (KCC2) that modulates effects of GABA [@pone.0048814-Barbato1]. Finally, miR-30e may regulate neuronal death as down-regulation of miR-30e expression promoted neuronal survival in long-lived calorie-restricted mice [@pone.0048814-Khanna1]. However, we were not able to validate differential expression of miRNA-30e in the exosome-containing samples of PFCs in SZ (data not shown). We found miR-29c to be significantly increased in the exosome-enriched preparations from PFC of individuals diagnosed with BD in comparison to controls according to SAM and qPCR analysis. Interestingly, the expression of miR-29c was not significantly different in BD cases compared to controls according to Wilcoxon test applied to our *Luminex* data (p-value 0.0649; [Table S3](#pone.0048814.s006){ref-type="supplementary-material"}). The fact that miR-29c was significantly differentially expressed in SAM ([Tables 2](#pone-0048814-t002){ref-type="table"} and [3](#pone-0048814-t003){ref-type="table"}), further confirmed by qPCR analysis in BD vs. controls ([Table 9](#pone-0048814-t009){ref-type="table"}), suggests that FDR testing through the use of SAM might be a superior strategy for discovery of true positives.

Like miR-497, the miRNA confirmed to be up-regulated in SZ samples, miR-29c was among the top-ranked in both SAM analyses ([Table 2](#pone-0048814-t002){ref-type="table"} and [3](#pone-0048814-t003){ref-type="table"}). In other words, both of these miRNAs were considered highly differentially regulated in both diseases according to SAM. Moreover, miR-29c was also reported by Perkins et al. to be differentially expressed miRNAs in PFC of SZ patients [@pone.0048814-Perkins1]. Interestingly, miR-29 together with miR-31, the top-ranked differentially expressed miRNA by SAM but not by qPCR ([Table S1](#pone.0048814.s004){ref-type="supplementary-material"}, [Table 8](#pone-0048814-t008){ref-type="table"}), was proposed to regulate several cell-adhesion machinery components that are affected in the pathogenesis of many diseases [@pone.0048814-Valastyan1]. The up-regulation of miR-29c in the cortical exosomes of BD patients is particularly intriguing because miR-29c is induced by canonical Wnt signaling [@pone.0048814-Kapinas1] that is antagonized by GSK-3, a know substrate of inhibition by lithium, a first line of therapy for BD [@pone.0048814-Valvezan1].

The interpretation of our findings has the following limitations. First, the relationship between exosomal and cellular miRNAs is not understood: is the exosomal miRNA aberration a part of pathogenesis, or a corrective attempt? Second, age-associated common brain pathology, may complicate the interpretation of our results, although vascular and early Alzheimer's disease-associated pathologies were relatively evenly distributed in our samples ([Table 1](#pone-0048814-t001){ref-type="table"}). Third, we were limited by a finite number of the samples available that fulfilled the RNA quality standards. However, the statistical methods we applied were developed specifically as a "non-parametric" test for miRNA expression studies. This test has a built-in mechanism for evaluating small sample sizes, and makes use of a "positive constant" standard error value as one of its formulaic variables. This ensures that miRNAs with small values are not elevated high in the rankings simply because they have a small standard error. By comparison t-tests often assign strong significance to miRNAs with small expression levels due to their small standard errors. The PAM and SAM programs we used are therefore optimal in dealing with irregular data with small sample size such as ours.

Fourth, our microarray examined the expression of 312 miRNA, while hundreds more are known to exist and thus may be important for the pathobiology of SZ and BD. Finally, due to the variable efficiency of the primers in our cDNA samples, we could carry qPCRs for only six miRNAs ([Table 8](#pone-0048814-t008){ref-type="table"}, [9](#pone-0048814-t009){ref-type="table"}) featured among our top-ranked in SAM analyses ([Tables 2](#pone-0048814-t002){ref-type="table"} and [3](#pone-0048814-t003){ref-type="table"}). Nevertheless, the results of qPCR validation are remarkable considering that we examined different samples from the ones analyzed in the microarray, in particular controls - most likely to exhibit highly variable miRNA expressions ([Figure 4](#pone-0048814-g004){ref-type="fig"}). Interestingly, our qPCR analysis did not validate SZ-associated highly significant up-regulation of miR-31 by Luminex assay ([Table 2](#pone-0048814-t002){ref-type="table"}, [Table S1](#pone.0048814.s004){ref-type="supplementary-material"}). Considering, however, that Gardiner et al. (2012) [@pone.0048814-Gardiner1] confirmed miR-31 down-regulation in PBMCs of SZ patients, miR-31 dysregulation in SZ cannot be ruled-out. Our search for exosome-derived biomarkers yielded two candidates, miR-497 and miR-29c, in the PFC of SZ and BD patients respectively, potentially offering a novel insight into the pathogenesis of these diseases. In addition, rapid development of exosome nanotechnology [@pone.0048814-Lakhal1] adds the promise of alternative therapeutics delivery [@pone.0048814-AlvarezErviti1]--[@pone.0048814-Zhuang1] to the emerging diagnostic potential of brain-derived exosomes in neuropsychiatric diseases.
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###### 

**RNA quality control.** Representative RNA (sample C13, RIN = 7.0; the sample closest to the average (6.96) and median (6.85) value for the set) yields two strong bands at 40 s and 45 s representing the 18 S and 28 S ribosomal RNA (A). The electropherogram shows a marker peak and the two ribosomal peaks corresponding to 18 S and 28 S subunits. RIN value on a scale of 1--10 is computed based on the presence of correct ribosomal peaks, the ratio between those peaks, and the extent of RNA fragmentation (B). Relationship between RIN and mRNA and miRNA profiles (C): Next to the ladder (left), total and small RNA profiles of three degradation stages of a single RNA sample are shown (RIN 8.4 =  not degraded, RIN 3.1 =  partially degraded, RIN 2.5 =  severely degraded). Note that both mRNA (RT PCR, middle) and miRNA (*Luminex,* right) profiles obtained from a sample with RIN 3.1 (low in comparison to the average RIN of 6.96 in this study) are still relatively similar to the profile obtained from a sample with high (8.4) RIN.

(TIF)

###### 

Click here for additional data file.

###### 

**RNase treatment effect on total RNA profile.** *Agilent RNA 6000 Pico* chips have the ability to resolve RNAs in the size range of 25 nt to 6000 nt (top row). *Agilent Small RNA* chips have superior resolving power for RNAs in the range of 4 nt to 150 nt only (bottom row). Electropherogram from *Pico* chip shows that in addition to miRNAs, our exosome preparations also contain higher molecular weight cellular RNAs of sizes up to 4000 nt. These higher molecular weight species cannot be seen with the small RNA chips. Digesting exosome preparations with RNase A or a combination of RNase A and RNase T1 destroys the higher molecular weight extra-exosomal cellular RNAs and preserves only the small RNAs contained in the exosome itself. Note, also, that the fluorescent units scale \[FU\] on the Y-axis of all of the electropherograms represents the quantity of RNA. As such, RNase treated preps contain much less RNA than untreated preps as the exosomal RNA represents a small portion of the cellular RNA. Similarly, RNase digestion reduces both the size and amount of small RNAs present in exosomal preparations. Exosomal RNA preparations not treated with RNase contain more and larger RNAs in the 4--150+ nt range than do preparations treated with RNase A alone or RNases A and T1. The expected size ranges of miRNAs (∼19--28 nt, yellow) and pre-miRNAs (45--60 nt, blue) are indicated in the small RNA assay panels (bottom row). RNAs in these size ranges are well represented in our purified exosomal RNA preparations.

(TIF)

###### 

Click here for additional data file.

###### 

***NCode*** **amplification of exosome-derived RNA.** Amplification of miRNAs (which have no poly-A tails) requires the addition of a 3′ Oligo(dT) 24-mer as well as a 5′ T7 promoter template, which increases the size of each miRNA by ∼40 nt. In this case, the expected size range of amplified miRNAs is ∼60 nt (arrow) as opposed to that of the native ∼20 nt species. Profiles of amplified miRNA upon treatment with RNase A (green), without RNase (blue), and with RNase A/T1 (red -- optimal for exosome-derived RNA used in *Luminex* assay) are similar.

(TIF)

###### 

Click here for additional data file.

###### 

**Student's T tests of** ***Luminex*** **miRNA expression data with corrected p-values.**

(DOCX)

###### 

Click here for additional data file.

###### 

**Quantities of exosome-derived miRNA from the analyzed cases for** ***Luminex*** **assay, before and after** ***NCode*** **amplification.**

(DOCX)

###### 

Click here for additional data file.

###### 

**Wilcoxon non-parametric test and fold change for top BD hits as means for statistical verification.** 12 top-ranked miRNAs according to SAM in [Table 3](#pone-0048814-t003){ref-type="table"}, with q-values lower than 15%, ending with miR-526b\* - the last miRNA to have significantly changed expression in BD according to this test. miRNAs 219, 380--3p, 148a, 520a, and 526b\* (p-values in bold) have significantly changed expression in BD cases in comparison to controls by this analysis. The expression of miR-29c is not significantly different in BD cases according to Wilcoxon test (p-value 0.0649; see Discussion).

(DOCX)

###### 

Click here for additional data file.

###### 

**Phenotype traits (tobacco, alcohol, and recreational drug use) of analyzed cases.**

(DOCX)

###### 

Click here for additional data file.

###### 

**An ANOVA analysis of differences in age between C, BD, and SZ groups of cases.** No significant difference in age between the groups exists.

(DOCX)

###### 

Click here for additional data file.
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